Abstract
AbstractBackground & AimsPreserved performance status (PS) and liver function are required for systemic therapy in patients with advanced hepatocellular carcinoma (aHCC). We investigated the frequency of suitability for further systemic therapies following sorafenib in aHCC.MethodsDemographic, tumour and therapy‐related data were collected retrospectively for patients with aHCC who received sorafenib at a UK tertiary referral centre (training cohort), and an independent French centre (validation cohort). The primary endpoint was percentage of patients with Child‐Pugh class A (CP‐A) liver disease and PS 0–1 after sorafenib discontinuation.ResultsSorafenib was received by 182 patients. After sorafenib discontinuation, 93 patients (51%) were CP‐A and 60 patients (33%) were PS 0–1; 43 patients (24%) were both CP‐A and PS 0–1. On multivariable analysis, patients with Albumin‐Bilirubin (ALBI) score of 1 at time of sorafenib commencement were more likely to be suitable for post‐sorafenib therapy, (44% grade 1 vs 15% grade 2) (OR 3.76, 95%CI 1.72–8.25, P = .0009). In the validation cohort of 216 patients baseline ALBI grade was also significantly associated with suitability for further systemic therapy (P = .008).ConclusionsMost patients with aHCC are not suitable for further systemic therapy after sorafenib, but those with ALBI grade 1 have a greater likelihood of suitability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
